Literature DB >> 24836396

Modeling spontaneous metastatic renal cell carcinoma (mRCC) in mice following nephrectomy.

Amanda Tracz1, Michalis Mastri1, Christina R Lee2, Roberto Pili1, John M L Ebos3.   

Abstract

One of the key challenges to improved testing of new experimental therapeutics in renal cell carcinoma (RCC) is the development of models that faithfully recapitulate early- and late-stage metastatic disease progression. Typical tumor implantation models utilize ectopic or orthotopic primary tumor implantation, but few include systemic spontaneous metastatic disease that mimics the clinical setting. This protocol describes the key steps to develop RCC disease progression stages similar to patients. First, it uses a highly metastatic mouse tumor cell line in a syngeneic model to show orthotopic tumor cell implantation. Methods include superficial and internal implantation into the sub-capsular space with cells combined with matrigel to prevent leakage and early spread. Next it describes the procedures for excision of tumor-bearing kidney (nephrectomy), with critical pre- and post- surgical mouse care. Finally, it outlines the steps necessary to monitor and assess micro-and macro-metastatic disease progression, including bioluminescent imaging as well provides a detailed visual necropsy guide to score systemic disease distribution. The goal of this protocol description is to facilitate the widespread use of clinically relevant metastatic RCC models to improve the predictive value of future therapeutic testing.

Entities:  

Mesh:

Year:  2014        PMID: 24836396      PMCID: PMC4183115          DOI: 10.3791/51485

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.355


  14 in total

1.  Characterization of the invasive and metastatic phenotype in human renal cell carcinoma.

Authors:  I Saiki; S Naito; J Yoneda; I Azuma; J E Price; I J Fidler
Journal:  Clin Exp Metastasis       Date:  1991 Nov-Dec       Impact factor: 5.150

2.  An orthotopic model of serous ovarian cancer in immunocompetent mice for in vivo tumor imaging and monitoring of tumor immune responses.

Authors:  Selene Nunez-Cruz; Denise C Connolly; Nathalie Scholler
Journal:  J Vis Exp       Date:  2010-11-28       Impact factor: 1.355

3.  An open letter to the FDA and other regulatory agencies: Preclinical drug development must consider the impact on metastasis.

Authors:  Patricia S Steeg; Robin L Anderson; Menashe Bar-Eli; Ann F Chambers; Suzanne A Eccles; Kent Hunter; Kazuyuki Itoh; Yibin Kang; Lynn M Matrisian; Jonathan P Sleeman; Dan Theodorescu; Erik W Thompson; Danny R Welch
Journal:  Clin Cancer Res       Date:  2009-07-15       Impact factor: 12.531

4.  Preclinical therapeutic response of residual metastatic disease is distinct from its primary tumor of origin.

Authors:  Chi-Ping Day; John Carter; Carrie Bonomi; Melinda Hollingshead; Glenn Merlino
Journal:  Int J Cancer       Date:  2011-04-20       Impact factor: 7.396

5.  Orthotopic implantation is essential for the selection, growth and metastasis of human renal cell cancer in nude mice [corrected].

Authors:  I J Fidler; S Naito; S Pathak
Journal:  Cancer Metastasis Rev       Date:  1990-09       Impact factor: 9.264

Review 6.  Mouse models of advanced spontaneous metastasis for experimental therapeutics.

Authors:  Giulio Francia; William Cruz-Munoz; Shan Man; Ping Xu; Robert S Kerbel
Journal:  Nat Rev Cancer       Date:  2011-02       Impact factor: 60.716

7.  A model of postsurgical advanced metastatic breast cancer more accurately replicates the clinical efficacy of antiangiogenic drugs.

Authors:  Eric Guerin; Shan Man; Ping Xu; Robert S Kerbel
Journal:  Cancer Res       Date:  2013-04-22       Impact factor: 12.701

8.  Endostatin neoadjuvant gene therapy extends survival in an orthotopic metastatic mouse model of renal cell carcinoma.

Authors:  Marina de Souza Braga; Karen Barbosa Chaves; Roger Chammas; Nestor Schor; Maria Helena Bellini
Journal:  Biomed Pharmacother       Date:  2011-12-21       Impact factor: 6.529

9.  Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis.

Authors:  John M L Ebos; Christina R Lee; William Cruz-Munoz; Georg A Bjarnason; James G Christensen; Robert S Kerbel
Journal:  Cancer Cell       Date:  2009-03-03       Impact factor: 31.743

10.  Combination therapy of interleukin-2 and sorafenib improves survival benefits and prevents spontaneous pulmonary metastasis in murine renal cell carcinoma models.

Authors:  Yosuke Amagai; Mitsunobu Matsumoto; Kanji Hojo; Motofumi Iguchi; Tooru Wada; Hidekazu Tanaka; Nobuyuki Ide; Akira Kato; Michitaka Shichijo; Kenji Abe
Journal:  Jpn J Clin Oncol       Date:  2010-01-27       Impact factor: 3.019

View more
  10 in total

1.  Modeling Spontaneous Metastasis following Surgery: An In Vivo-In Silico Approach.

Authors:  Sebastien Benzekry; Amanda Tracz; Michalis Mastri; Ryan Corbelli; Dominique Barbolosi; John M L Ebos
Journal:  Cancer Res       Date:  2015-10-28       Impact factor: 12.701

Review 2.  Prioritizing therapeutic targets using patient-derived xenograft models.

Authors:  K A Lodhia; A M Hadley; P Haluska; C L Scott
Journal:  Biochim Biophys Acta       Date:  2015-03-14

3.  Anti-Cancer Activity of PAK4/NAMPT Inhibitor and Programmed Cell Death Protein-1 Antibody in Kidney Cancer.

Authors:  Josephine F Trott; Omran Abu Aboud; Bridget McLaughlin; Katie L Anderson; Jaime F Modiano; Kyoungmi Kim; Kuang-Yu Jen; William Senapedis; Hua Chang; Yosef Landesman; Erkan Baloglu; Roberto Pili; Robert H Weiss
Journal:  Kidney360       Date:  2020-05-28

4.  Adoptive T-Cell Therapy for Solid Tumors.

Authors:  Oladapo Yeku; Xinghuo Li; Renier J Brentjens
Journal:  Am Soc Clin Oncol Educ Book       Date:  2017

Review 5.  Choosing The Right Animal Model for Renal Cancer Research.

Authors:  Paweł Sobczuk; Anna Brodziak; Mohammed Imran Khan; Stuti Chhabra; Michał Fiedorowicz; Marlena Wełniak-Kamińska; Kamil Synoradzki; Ewa Bartnik; Agnieszka Cudnoch-Jędrzejewska; Anna M Czarnecka
Journal:  Transl Oncol       Date:  2020-02-22       Impact factor: 4.243

6.  Murine Tumor Models for Oncolytic Rhabdo-Virotherapy.

Authors:  Theresa Falls; Dominic Guy Roy; John Cameron Bell; Marie-Claude Bourgeois-Daigneault
Journal:  ILAR J       Date:  2016

7.  Neoadjuvant antiangiogenic therapy reveals contrasts in primary and metastatic tumor efficacy.

Authors:  John M L Ebos; Michalis Mastri; Christina R Lee; Amanda Tracz; John M Hudson; Kristopher Attwood; William R Cruz-Munoz; Christopher Jedeszko; Peter Burns; Robert S Kerbel
Journal:  EMBO Mol Med       Date:  2014-12       Impact factor: 12.137

8.  CRISPR-Mediated VHL Knockout Generates an Improved Model for Metastatic Renal Cell Carcinoma.

Authors:  Shiruyeh Schokrpur; Junhui Hu; Diana L Moughon; Peijun Liu; Lucia C Lin; Kip Hermann; Serghei Mangul; Wei Guan; Matteo Pellegrini; Hua Xu; Lily Wu
Journal:  Sci Rep       Date:  2016-06-30       Impact factor: 4.379

9.  Enhanced efficacy of sitravatinib in metastatic models of antiangiogenic therapy resistance.

Authors:  Melissa Dolan; Michalis Mastri; Amanda Tracz; James G Christensen; Gurkamal Chatta; John M L Ebos
Journal:  PLoS One       Date:  2019-08-01       Impact factor: 3.240

10.  Immunization with short peptide particles reveals a functional CD8+ T-cell neoepitope in a murine renal carcinoma model.

Authors:  Xuedan He; Shiqi Zhou; Melissa Dolan; Yuhao Shi; Jianxin Wang; Breandan Quinn; Dushyant Jahagirdar; Wei-Chiao Huang; Moriya Tsuji; Roberto Pili; Fumito Ito; Joaquin Ortega; Scott I Abrams; John M L Ebos; Jonathan F Lovell
Journal:  J Immunother Cancer       Date:  2021-12       Impact factor: 12.469

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.